Navigation Links
'Deranged calcium signaling' contributes to neurological disorder, UT Southwestern researchers find
Date:11/26/2008

DALLAS Nov. 25, 2008 Defective calcium metabolism in nerve cells may play a major role in a fatal genetic neurological disorder that resembles Huntington's disease, researchers at UT Southwestern Medical Center have found in a mouse study.

The disease, called spinocerebellar ataxia 3 also known as SCA3, or Machado-Joseph disease is a genetic disorder that, like Huntington's, impairs coordination, speech, and vision and causes brain atrophy. Although rare, the condition is one of the most common inherited forms of ataxia and most frequently affects people of Portuguese descent.

The UT Southwestern researchers previously had found that calcium flow within nerve cells is disrupted in Huntington's disease. The latest findings, appearing in the Nov. 26 issue of the Journal of Neuroscience, suggest that SCA3, which is caused by a genetic defect similar to the one found in Huntington's, involves the same "deranged calcium signaling," researchers said.

Both SCA3 and Huntington's are caused by repeating segments of DNA, although the repeats associated with each disease appear in different genes that code for different proteins. The genetic mutations cause repeated units of the amino acid glutamine to appear in the respective proteins. The more repeats there are, the earlier the onset of the disease.

In Huntington's disease the mutated protein is Huntingtin; in SCA3 it is ataxin-3.

The researchers determined that the mutant human ataxin-3 activates a molecule that acts as a channel in the membrane of a sequestered chamber inside cells called the endoplasmic reticulum, or ER. The channel then releases calcium into the cell as a whole. Normal ataxin-3 did not activate the channel or cause calcium release.

The researchers also found that cells from a person with SCA3 showed abnormally high levels of calcium release when treated with bradykinin, a substance that also activates the calcium channel.

Such abnormal calcium release is toxic to cells and results in impaired motor function, said Dr. Ilya Bezprozvanny, professor of physiology at UT Southwestern and senior author of the study. "We're generalizing the idea of calcium toxicity for this group of diseases, which are called polyglutamine expansion disorders," he said.

The researchers also studied mice that had been genetically engineered to overexpress the human ataxin-3 protein containing excessive glutamine repeats. The mutant mice performed poorly on tests of motor coordination compared with normal mice and displayed age-dependent neuronal loss in the same brain regions that are affected in SCA3 patients.

To test whether blocking calcium release would alleviate symptoms in the mice, the researchers treated them for a year with dantrolene, a drug that blocks excessive calcium release from the ER in skeletal muscle cells. Dantrolene is approved for use in humans as a one-time emergency treatment for a reaction to anesthesia.

Treatment with dantrolene improved the coordination of the mutant mice and slowed brain atrophy.

Dantrolene is not suitable for long-term use in humans, however, because of side effects that can potentially harm the liver and the heart and cause neurological problems, said Dr. Bezprozvanny.

"The take-home message is not so much that dantrolene is the solution for treating SCA3, but that this shows a direction for research into a better drug to block similar targets with fewer side effects," Dr. Bezprozvanny said.

The researchers now are studying whether blocking calcium release from the endoplasmic reticulum also can improve function in mouse models of Huntington's and other neurodegenerative diseases such as spinocerebellar ataxia type 2 and Alzheimer's disease.


'/>"/>

Contact: Aline McKenzie
aline.mckenzie@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related biology news :

1. Majority of osteoporosis patients not receiving calcium and vitamin D with treatment
2. Measuring calcium in serpentine soils
3. Prevent a bone break, drink milk to boost calcium
4. Vitamin D and calcium influence cell death in the colon, researchers find
5. Community-intervention study links successful town makeover focused on boosting calcium and exercise
6. Genetically modified carrots provide more calcium
7. Got carrots? Vegetables may have bone to pick as calcium providers
8. Got calcium? UWM researcher finds that food labels confuse consumers
9. Dietary calcium could possibly prevent the spread of breast cancer to bone
10. Breast cancer treatment resistance linked to signaling pathway
11. Imiquimod, an immune response modifier, is dependent on the OGF-OGFr signaling pathway
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Deranged calcium signaling' contributes to neurological disorder, UT Southwestern researchers find
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
(Date:6/22/2016)... 22, 2016 Research and Markets has announced ... report to their offering. ... from $29.3 billion in 2013. The market is expected to grow ... 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 ... during the forecast period (2015 to 2020) are discussed. As well, ...
Breaking Biology Technology: